Mediastinitis medical therapy: Difference between revisions
Jump to navigation
Jump to search
YazanDaaboul (talk | contribs) No edit summary |
|||
| Line 2: | Line 2: | ||
{{Mediastinitis}} | {{Mediastinitis}} | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
The mainstay of therapy in acute mediastinitis includes [[Clindamycin]] and [[Ceftriaxone]]. The preferred regimen for prophylaxis against acute mediastinitis includes either [[Vancomycin]] or a second generation [[Cephalosporin]]. | The mainstay of therapy in acute mediastinitis includes [[Clindamycin]] and [[Ceftriaxone]]. The preferred regimen for prophylaxis against acute mediastinitis includes either [[Vancomycin]] or a second generation [[Cephalosporin]]. | ||
| Line 23: | Line 20: | ||
::* Note (4): Use of a continuous intravenous [[insulin]] protocol to achieve and maintain an early postoperative blood [[glucose]] concentration less than or equal to 180 mg/dL while avoiding [[hypoglycemia]] is indicated to reduce the risk of deep sternal wound [[infection]]. | ::* Note (4): Use of a continuous intravenous [[insulin]] protocol to achieve and maintain an early postoperative blood [[glucose]] concentration less than or equal to 180 mg/dL while avoiding [[hypoglycemia]] is indicated to reduce the risk of deep sternal wound [[infection]]. | ||
::* Note (5): The use of intranasal [[mupirocin]] is reasonable in nasal carriers of [[S. aureus]]. | ::* Note (5): The use of intranasal [[mupirocin]] is reasonable in nasal carriers of [[S. aureus]]. | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Thorax]] | [[Category:Thorax]] | ||
[[Category:Pulmonology]] | [[Category:Pulmonology]] | ||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
Revision as of 21:44, 12 August 2015
|
Mediastinitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mediastinitis medical therapy On the Web |
|
American Roentgen Ray Society Images of Mediastinitis medical therapy |
|
Risk calculators and risk factors for Mediastinitis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The mainstay of therapy in acute mediastinitis includes Clindamycin and Ceftriaxone. The preferred regimen for prophylaxis against acute mediastinitis includes either Vancomycin or a second generation Cephalosporin.
Medical Therapy
Acute mediastinitis treatment
- Treatment secondary to cardiac infection and surgery[1].
- Preferred regimen: Clindamycin 450 mg IV q6h AND Ceftriaxone 2 g IV q24h, for at least 2 weeks
- Prophylaxis
- Methicillin susceptible staphylococcus aureus infection
- Preferred regimen: Second generation cephalosporin.
- Methicillin susceptible staphylococcus aureus infection
- Preferred regimen: Vancomycin
- Note (1): Preoperative antibiotics should be administered to all patients to reduce the risk of mediastinitis in cardiac surgery.
- Note (2): A deep sternal wound infection should be treated with aggressive surgical debridement in the absence of complicating circumstances.
- Note (3): Primary or secondary closure with muscle or omental flap is recommended. Vacuum therapy in conjunction with early and aggressive debridement is an effective adjunctive therapy.
- Note (4): Use of a continuous intravenous insulin protocol to achieve and maintain an early postoperative blood glucose concentration less than or equal to 180 mg/dL while avoiding hypoglycemia is indicated to reduce the risk of deep sternal wound infection.
- Note (5): The use of intranasal mupirocin is reasonable in nasal carriers of S. aureus.
References
- ↑ Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG; et al. (2011). "2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons". J Am Coll Cardiol. 58 (24): e123–210. doi:10.1016/j.jacc.2011.08.009. PMID 22070836.